In race to lead the TIGIT pack in I/O, Roche delivers positive PhII data — but big questions linger
Expectations over Roche’s anti-TIGIT drug tiragolumab have been growing steadily in the buildup to ASCO. As the lead drug in the field pursuing second …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
